CDK5RAP1 deficiency induces cell cycle arrest and apoptosis in human breast cancer cell line by the ROS/JNK signaling pathway

HONGBIN WANG, LI WEI, CHANGLI LI, JING ZHOU and ZHIGAO LI

Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China

Received July 8, 2014; Accepted August 21, 2014

DOI: 10.3892/or.2015.3736

Abstract. Cyclin-dependent kinase 5 regulatory subunit associated protein 1 (CDK5RAP1) is an enzyme which post-synthetically converts the RNA modification N6-isopentenyladenosine (i6A) into 2-methylthio-N6-isopentenyladenosine (ms2i6A). However, the interaction between CDK5RAP1 deficiency and cell apoptosis has not been studied. Breast cancer has long been a leading cause of mortality in the world. Therefore, in the present study, CDK5RAP1 deficiency in a human breast cancer cell line was investigated. CDK5RAP1 small interfering RNA (siRNA) and negative control siRNA were transfected into MCF-7 cells, and the cells were further incubated for 48 h. CDK5RAP1 deficiency suppressed tumor growth in MCF-7 cells and arrested the cells at G2/M phase. CDK5RAP1 deficiency also induced cell apoptosis and reactive oxygen species (ROS) generation. Furthermore, western blot analysis showed that the expression of phospho-c-Jun N-terminal kinase (p-JNK), p53, caspase-9 and caspase-3 were upregulated in CDK5RAP1-deficient MCF-7 cells. Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells. Taken together, these data indicated that CDK5RAP1 deficiency induced cell cycle arrest and apoptosis in human breast cancer MCF-7 cells by the ROS/JNK signaling pathway. Our findings indicated a novel therapeutic strategy for cancer.

Introduction

Cyclin-dependent kinase 5 regulatory subunit associated protein 1 (CDK5RAP1) is a radical S-adenosyl methionine (SAM) enzyme (1) with homology to the bacterial MiaB protein (2), which post-synthetically converts the RNA modification N6-isopentenyladenosine (i6A) into 2-methylthio-N6-isopentenyladenosine (ms2i6A) (3). It was discovered to inhibit the active CDK5 kinase and function in codon suppression (4) and stabilization of the codon/anticodon interaction (5). CDK5 aberrant regulation can lead to a number of diseases (6). The biochemical link established by CDK5RAP1 between the enzymatic modification of transfer RNA (tRNA) tanticodon loops and CDK5 kinase activity is highly unusual, particularly since the modified base ms2i6A is known to exist in tRNA of prokaryotic origin (7), particularly in mitochondrial tRNA of mammals (8).

Breast cancer has long been a leading cause of mortality in women worldwide (9). Due to the limited efficacy of traditional therapy, it is necessary to exploit a new treatment strategy for breast cancer. Mitochondria-initiated responses are thought to be the major pathway for apoptosis, and, therefore, targeting the mitochondria is a novel strategy for cancer therapy (10). Hence, in the present study, we sought to determine if the mistranslation of ms2i6A in mitochondrial tRNA caused by CDK5RAP1 deficiency affects the human breast cancer cell line, MCF-7 cells.

Cell cycle arrest is an important cause of growth inhibition. Many anticancer agents reduce malignant growth by arresting the cell cycle at the G1, S or G2/M phases (11). Arresting the cell cycle is an effective method to regulate cell cycle progression, and to contribute to malignant cell proliferation (12). Apart from cell cycle arrest, apoptosis is another cause of growth inhibition. There is compelling evidence that excessive reactive oxygen species (ROS) production surmounts cellular antioxidant defenses, triggering apoptosis (13), and cancer cells are more sensitive to rapid increases in ROS levels than normal cells. Oncogenic transformation elevates basal ROS levels significantly so that any further acute increases can trigger reactivation of the apoptotic program in cancer cells (14). Various apoptotic stimuli can rapidly activate MAPKs, which include phospho-c-Jun N-terminal kinase (p-JNK) (15). The activation of JNK is associated with ROS elevation (16). The p-JNK activated through ROS-dependent pathway induces the overexpression of tumor suppressors, such as p53, then leads to cell apoptosis (17).

In the present study, to the best of our knowledge, the hypothesis that CDK5RAP1 deficiency inhibits tumor growth in a human breast cancer cell line was explored for the first time. The results showed that CDK5RAP1 deficiency induced MCF-7 cell cycle arrest and apoptosis, which could be...
prevented by the pretreatment with N-acetyl-cysteine (NAC; the inhibitor of ROS), or SP600125 (the inhibitor of JNK), suggesting that the ROS/JNK signaling pathway is an important mechanism in the apoptosis process. Our study indicated that this may be a novel therapeutic strategy for cancer.

Materials and methods

Cell culture. The human breast cancer cell line MCF-7 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). This study was performed in accordance with the Experiment Guidelines of Harbin Medical University (Harbin, China) and ethical approval was obtained from Harbin Medical University. MCF-7 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO, Grand Island, NY, USA), and were cultured in an incubator (Sanyo, Tokyo, Japan) with 5% CO₂ at 37°C.

Small interfering RNA (siRNA) transfection. CDK5RAP1 siRNA and non-targeted negative control siRNA were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). MCF-7 cells were seeded onto 6-well plates at the recommended density (1x10⁵ cells/well) and grown to 60-80% confluence prior to transfection. siRNAs were transfected into MCF-7 cells with siRNA Transfection Reagent (Santa Cruz Biotechnology Inc.) according to the manufacturer's instructions. MCF-7 cells were further incubated for another 48 h and then used for experiments.

Quantitative polymerase chain reaction (qPCR). CDK5RAP1 siRNA and negative control siRNA were transfected into MCF-7 cells, and the cells were further incubated for 48 h. Total RNA was extracted from MCF-7 cells and relative mRNA was normalized to 18s. The following primers (Hokkaido System Science Co. Ltd. Sapporo, Japan) were used: CDK5RAP1 forward, 5'-ATGGCTGCCAGATGAATGTGA-3' and reverse, 5'-CTCTTGGAGGTTACTGGTCCG-3'; 18s forward, 5'-GTAACCCGTTGAACCCCATT-3' and reverse, 5'-CCATCCAATCGGTAGTAGCG-3'. qPCR was performed using the ABI 7300 Fast real-time PCR system (Applied Biosystems, Foster City, CA, USA).

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The viability of normal MCF-7 cells and CDK5RAP1-deficient MCF-7 cells was determined by a colorimetric MTT assay according to the method described previously (18). Absorbance at 550 nm was determined by an MTP-800 microplate reader (Corona Electric, Tokyo, Japan). Absorbance at 690 nm was also measured to compensate for
any interfering effects of cell debris and the microtiter plate. Percentage of viable cell number was calculated as: Optical density (OD) of treated sample/OD of untreated control x100.

**Cell cycle analysis.** CDK5RAP1 siRNA and negative control siRNA were transfected into MCF-7 cells, and the cells were further incubated for 48 h. Then, MCF-7 cells were trypsinized and fixed in 99% ethanol at -20°C for 2 h, washed and re-suspended in 420 µl PBS. Subsequently, samples were first incubated with RNase A (Sigma, Shanghai, China) (50 µl of a 10 mg/ml solution) at 37°C for 30 min, and then PI (20 µl of a 0.2 mg/ml solution) at room temperature for 10 min. DNA content was analyzed by flow cytometry using a FACSCalibur and CellQuest software (Becton Dickinson, Franklin Lake, NJ, USA), as previously described (19).

**Apoptosis assay.** MCF-7 cell apoptosis staining was performed using an Annexin V (cell apoptosis signaling component)-Biotin Apoptosis kit as per the manufacturer's instructions (Mountain View, CA, USA). The MCF-7 cells were seeded in a 6-well plate at the density of 1x10^5 cells/well and were pretreated or non-treated with NAC (5 mM) or SP600125 evaluation. Nuclear staining with Hoechst 33342 for morphological ware. Ten thousand events were collected for each sample.

**Western blot analysis.** Electrophoresis was performed using a vertical slab gel with 12% polyacrylamide content according to the method described previously (21). The transfer of proteins from the SDS polyacrylamide gel to a membrane was performed electrophoretically according to the method described previously (22) with certain modifications using a Semi Dry Electrobolter (Sartorius AG, Goettingen, Germany) for 90 min with an electric current of 15 V. The membrane was treated with Block Ace™ (4%) for 30 min at 22°C. The first reaction was performed using rabbit immunoglobulin (IG) G antibodies against JNK, p-JNK, p53, caspase-9 and caspase-3 (Sigma) in PBS containing 0.03% Tween-20 for 1 h at 22°C. Following washing in the same buffer, the second reaction was performed using horseradish peroxidase (HRP)-conjugated anti-rabbit goat IgG (20 ng/ml) for 30 min at 22°C. After washing, the enhanced chemiluminescence (ECL) reaction was performed on the membrane using the ECL Plus Western Blotting Detection System™ (GE Healthcare Life Sciences).

**Statistical analysis.** Data are expressed as the mean ± standard deviation. Each experiment was repeated at least 3 times. The Student’s t-test was used and P<0.05 was considered to indicate a statistically significant difference.

**Results**

**CDK5RAP1 deficiency suppresses tumor growth in MCF-7 cells.** To investigate the effect of CDK5RAP1 deficiency on the growth of human breast cancer cell line (MCF-7 cells), MCF-7 cells were seeded onto 6-well plates at the recommended density (1x10^5 cells/well) and grown to 60-80% confluence prior to transfection. CDK5RAP1 siRNA and negative control siRNA were transfected into MCF-7 cells, and then the cells were further incubated for 48 h. The viability of normal MCF-7 cells and CDK5RAP1-deficient MCF-7 cells was determined by a colorimetric MTT assay. The tumor growth was significantly suppressed in the CDK5RAP1-deficient MCF-7 cells (Fig. 2A and B; P<0.01).

**CDK5RAP1 deficiency arrests MCF-7 cells at the G2/M phase.** CDK5RAP1 siRNA and negative control siRNA were transfected into MCF-7 cells, and then the cells were further incubated for 48 h. Cell cycle analysis was performed using a FACSCalibur and CellQuest software. CDK5RAP1 deficiency arrested MCF-7 cells at the G2/M phase significantly compared with control MCF-7 cells (Fig. 2C and D; P<0.01).

**CDK5RAP1 deficiency induces MCF-7 cell apoptosis.** MCF-7 cells were plated in 6-well plates at the density of 1x10^5 cells/well. CDK5RAP1 siRNA and negative control siRNA were transfected into MCF-7 cells, and the cells were further incubated for 48 h. MCF-7 cells were then washed with PBS and labeled with 10 µM DCFDA for 30 min. Then, excess DCFH-DA was removed by washing the cells in serum-free RPMI-1640 medium (Sigma). The fluorescence intensities were measured using a FACSCalibur flow cytometer (BD Biosciences).

**Intracellular accumulation.** Intracellular accumulation of ROS was estimated using the fluorescent dye H2-DCFDA (Life Technologies, Tokyo, Japan), which is converted to a membrane impermeable and highly fluorescent compound, dichlorofluorescin diacetate (DCF), in the cell in the presence of ROS (20). The MCF-7 cells were seeded in a 6-well plate at the density of 1x10^5 cells/well. Following transfection with CDK5RAP1 siRNA or control siRNA, MCF-7 cells were further incubated for 48 h. The cells were rinsed with a serum-free medium and were incubated in 5 µM H2-DCFDA for 60 min at 37°C. The cells were then examined under a fluorescence microscope (C1-T-SM; Nikon, Tokyo, Japan), collected and subjected to a fluorescence spectrophotometer (F-2500; Hitachi, Tokyo, Japan) to detect the fluorescence of DCF inside cells (excitation, 488 nm; emission, 521 nm).
1x10⁵ cells/well. Following transfection with CDK5RAP1 siRNA or control siRNA, MCF-7 cells were further incubated for 48 h. The MCF-7 cell apoptosis was performed using an Annexin V-Biotin Apoptosis kit and nuclear staining with Hoechst 33342 by fluorescence microscopy. CDK5RAP1 deficiency induced MCF-7 cell apoptosis significantly compared with control MCF-7 cells (Fig. 3A and B, Annexin V-Biotin; Fig. 3C and D, Hoechst 33342 staining. P<0.01).

CDK5RAP1 deficiency induces ROS generation in MCF-7 cells. CDK5RAP1 siRNA and negative control siRNA were transfected into MCF-7 cells, and then the cells were further incubated for 48 h. Intracellular accumulation of ROS was estimated using the fluorescent dye H₂DCFDA (Fig. 3E and G), and flow cytometry using DCFH-DA (Fig. 3F). CDK5RAP1 deficiency significantly induced ROS generation in MCF-7 cells (P<0.01).

CDK5RAP1 deficiency upregulates the expression of p-JNK, p53, caspase-9 and caspase-3 in MCF-7 cells. MCF-7 cells were plated in 6-well plates at the density of 1x10⁵ cells/well. After transfection with CDK5RAP1 siRNA or control siRNA, MCF-7 cells were further incubated for 48 h. The expression levels of p-JNK, p53, caspase-9 and caspase-3 in MCF-7 cells were measured by western blot analysis. CDK5RAP1 deficiency upregulated the expression of p-JNK, p53, caspase-9 and caspase-3 significantly compared with control MCF-7 cells. β-actin was used as the normalization (Fig. 4).

NAC and SP600125 prevent MCF-7 cell apoptosis induced by CDK5RAP1 deficiency. The MCF-7 cells were seeded in a 6-well plate at the density of 1x10⁵ cells/well and were pretreated or non-treated with NAC (5 mM) or SP600125 (5 µM) for 1 h prior to CDK5RAP1 siRNA transfection. Following transfection with CDK5RAP1 siRNA or control siRNA, MCF-7 cells were further incubated for 48 h. CDK5RAP1 deficiency induced MCF-7 cell apoptosis significantly compared with control MCF-7 cells, while pretreatment with NAC or SP600125 prevented the CDK5RAP1 deficiency-induced apoptosis significantly (Fig. 5A and B; P<0.01).
NAC and SP600125 prevent the CDK5RAP1 deficiency-induced high expression of p-JNK, p53, caspase-9, and caspase-3 in MCF-7 cells. The MCF-7 cells were pretreated or non-treated with NAC (5 mM) or SP600125 (5 µM) for 1 h prior to CDK5RAP1 siRNA transfection. After transfection with CDK5RAP1 siRNA or control siRNA, MCF-7 cells were further incubated for 48 h. CDK5RAP1 deficiency upregulated the expression of p-JNK, p53, caspase-9, and caspase-3 significantly compared with control MCF-7 cells. While pretreatment with NAC or SP600125 prevented the CDK5RAP1 deficiency-induced high expression of p-JNK, p53, caspase-9, and caspase-3 in MCF-7 cells, β-actin was used as the normalization.

Discussion

The present study demonstrated, to the best of our knowledge for the first time, that CDK5RAP1 deficiency suppresses tumor growth and induces cell cycle arrest and apoptosis in a human breast cancer cell line (MCF-7 cells). CDK5RAP1 is a radical SAM enzyme (1) with homology to the bacterial
MiaB protein (2), which post-synthetically converts the RNA modification i6A into ms2i6A (3-6) (Fig. 1A). The biochemical link established by CDK5RAP1 between the enzymatic modification of tRNA tanticodon loops and CDK5 kinase activity is highly unusual, particularly since the modified base ms2i6A is known to exist in tRNA of prokaryotic origin (7), particularly in mitochondrial tRNA of mammals (8).

Breast cancer has long been a leading cause of mortality in women of developed and developing countries (9,23). Cell cycle arrest is an important cause of growth inhibition. Many anticancer agents exhibit anti-proliferation by inhibiting cell cycle progression at a particular check point such as G0/G1, S, or G2/M (11). Deregulation of cell cycle has been linked with cancer initiation and progression (24). Arresting the cell cycle is an effective method to regulate cell cycle progression, and contribute to malignant cell proliferation (12). It has been reported that the expression of CDK5RAP1 gene is related to the regulation and progression of the M phase of the cell cycle (25). In accordance with that, our present study confirmed that CDK5RAP1 deficiency suppressed tumor growth in MCF-7 cells and arrested the cells at G2/M phase (Fig. 2). Apart from cell cycle arrest, apoptosis is another cause of growth inhibition (26). Apoptosis, or programmed cell death, is an essential mechanism through which many types of chemotherapeutic agents inhibit tumor growth (27). Mitochondria-initiated responses are thought to be the major pathway for apoptosis, and, therefore, targeting the mitochondria is a novel strategy for cancer therapy (10). Our present study also confirmed that CDK5RAP1 deficiency induced MCF-7 cell apoptosis (Fig. 3A-D).

Figure 5. N-acetyl-cysteine (NAC; the inhibitor of ROS) and SP600125 (the inhibitor of JNK) prevent the effect of cyclin-dependent kinase 5 regulatory subunit associated protein 1 (CDK5RAP1) deficiency on MCF-7 cells. The MCF-7 cells were seeded in a 6-well plate at the density of 1x10^5 cells/well and were pretreated or non-treated with NAC (5 mM) or SP600125 (5 µM) for 1 h prior to CDK5RAP1 small interfering RNA (siRNA) transfection. After transfection with CDK5RAP1 siRNA or control siRNA, MCF-7 cells were further incubated for 48 h. (A) Pretreatment with NAC or SP600125 prevented the CDK5RAP1 deficiency-induced apoptosis. (B) Quantification of (A). (C) CDK5RAP1 deficiency-induced high expression of phospho-c-Jun N-terminal kinase (p-JNK), p53, caspase-9 and caspase-3 in MCF-7 cells was prevented by the pretreatment with NAC or SP600125. β-actin was used as the normalization. Data are expressed as the mean ± standard deviation (n=5). *P<0.05 was considered to indicate a statistically significant difference (*P<0.01; CDK5RAP1 knockdown vs control; **P<0.01, NAC and SP600125 vs CDK5RAP1 knockdown).

ROS, which is the byproduct of normal cellular oxidative processes, has been suggested to regulate the process involved in the initiation of apoptotic signaling (28) and has been implicated in several oncogenic pathways. Although it...
has been reported to be a tumor growth promoter (29), there is compelling evidence that ROS production surmounts cellular antioxidant defenses, triggering apoptosis (13), and cancer cells are more sensitive to rapid increases in ROS levels than normal cells. ROS-mediated cytotoxicity has also been identified as an important mechanism in some anticancer agents (30). Accumulating evidence indicates that many anticancer agents destroy tumor cells by raising the level of ROS above a toxic threshold (31). Oncogenic transformation elevates basal ROS levels significantly so that any further acute increases can trigger reactivation of the apoptotic program in cancer cells (14). High level of ROS can destroy the integrity of plasma membrane, affect dynamic of actin cytoskeleton and cause DNA damage, cumulatively known as oxidative stress (32). To investigate whether CDK5RAP1 deficiency-induced MCF-7 cell apoptosis is promoted through an increase in ROS production, we measured ROS levels. Our results showed that CDK5RAP1 deficiency induced cell ROS generation in MCF-7 cells significantly (Fig. 3E-G).

Various apoptotic stimuli can rapidly activate MAPKs, which include p-JNK (15). The activation of JNK is associated with ROS elevation (16). A previous study suggested that activation of JNK through ROS generation is important for apoptosis (33). To investigate this hypothesis, we examined the expression of p-JNK in the CDK5RAP1-deficient MCF-7 cells. The p-JNK activated through ROS-dependent pathway induces the overexpression of tumor suppressors, such as p53 (17), p73, a tumor suppressor protein, triggers cell cycle arrest to provide time for self-mediated apoptosis through transcriptional activation of cyclin-dependent kinase inhibitor (34). In addition to cell cycle arrest, p53 can induce the expression of several factors involved in apoptosis, such as caspase-9 and caspase-3 (35). The activation of caspase-9 and caspase-3 damage the cell structure and cause functional disorder by proteolysis, final induction of apoptosis (36). Our data demonstrated that the expression of p-JNK, p53, caspase-9 and caspase-3 were all upregulated in CDK5RAP1-deficient MCF-7 cells (Fig. 4). This suggests that p-JNK, p53, caspase-9 and caspase-3 are all involved in the apoptosis process. As shown in Fig. 5, pretreatment with NAC (the inhibitor of ROS) or SP600125 (the inhibitor of JNK), prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells. These results clearly indicate that CDK5RAP1 deficiency induces the mitochondrial apoptosis by the ROS/JNK signaling pathway.

CDK5RAP1 deficiency induces cell cycle arrest and apoptosis in MCF-7 cells via ROS generation, resulting p-JNK and p53 activation, increase in cleavage of caspase-9 and caspase-3, according to the mechanism described in Fig. 6. Although our data provided evidence that tumor growth was markedly inhibited in the CDK5RAP1-deficient MCF-7 cells, the complex process and mechanism require further investigation in the future.

In the present study, to the best of our knowledge, we demonstrated for the first time that CDK5RAP1 deficiency induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells by the ROS/JNK signaling pathway. The potential of CDK5RAP1 deficiency in cancer cells is expected to provide key insight into the development of novel clinical treatments for cancer.

References


